These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 16564946

  • 1. Acquired hemophilia in association with ANCA-associated vasculitis: response to rituximab.
    Clatworthy MR, Jayne DR.
    Am J Kidney Dis; 2006 Apr; 47(4):680-2. PubMed ID: 16564946
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
    Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D.
    Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
    [Abstract] [Full Text] [Related]

  • 4. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
    Keogh KA, Wylam ME, Stone JH, Specks U.
    Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M, Chaudhry A, Jayne D.
    Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ, Fenske TS, Blinder MA.
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU, Gross WL.
    J Autoimmun; 2009 Jan; 32(3-4):163-71. PubMed ID: 19345067
    [Abstract] [Full Text] [Related]

  • 11. Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?
    Wong CF.
    Nephrol Dial Transplant; 2007 Jan; 22(1):32-6. PubMed ID: 17056639
    [No Abstract] [Full Text] [Related]

  • 12. Rituximab for adolescents with haemophilia and high titre inhibitors.
    Fox RA, Neufeld EJ, Bennett CM.
    Haemophilia; 2006 May; 12(3):218-22. PubMed ID: 16643204
    [Abstract] [Full Text] [Related]

  • 13. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases.
    Feldmann M, Pusey CD.
    J Am Soc Nephrol; 2006 May; 17(5):1243-52. PubMed ID: 16624928
    [Abstract] [Full Text] [Related]

  • 14. Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA-associated vasculitis.
    Golbin JM, Specks U.
    Clin Exp Rheumatol; 2007 May; 25(1 Suppl 44):S74-6. PubMed ID: 17428376
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).
    Niedermeier A, Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M.
    Arch Dermatol; 2007 Feb; 143(2):192-8. PubMed ID: 17309999
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.